Opaleye Management’s Xenon Pharmaceuticals XENE Stock Holding History

Opaleye Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-465,200	Closed	-$7.01M	–	54
2018 Q3	$7.01M	Buy	+465,200	New	+$5.39M	1.78%	20
2017 Q2	–	Sell	-360,000	Closed	-$1.44M	–	49
2017 Q1	$1.44M	Sell	360,000 -45,000	-11%	-$354K	0.72%	33
2016 Q4	$3.12M	Sell	405,000 -5,000	-1%	-$40.2K	1.84%	20
2016 Q3	$3.32M	Hold	410,000	–	–	1.74%	22
2016 Q2	$2.42M	Buy	410,000 +10,000	+3%	+$68.6K	1.62%	24
2016 Q1	$2.8M	Buy	400,000 +100,000	+33%	+$719K	1.74%	24
2015 Q4	$2.41M	Buy	300,000 +148,700	+98%	+$1.27M	1.01%	37
2015 Q3	$1.25M	Buy	+151,300	New	+$1.5M	0.62%	41

Other funds holding XENE

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Opaleye Management's XENE Position: Q4 2018 in Review

Opaleye Management sold out of Xenon Pharmaceuticals (XENE) in Q4 2018, closing a stake of 465,200 shares — an estimated $7.01M sold.

Opaleye Management first reported a position in XENE in Q3 2015 and held it in 8 quarters. The position peaked at $7.01M in Q3 2018. 58 funds tracked by Wall St. Rank hold XENE as of Q4 2018.

Opaleye Management reported no remaining Xenon Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Opaleye Management sold 465,200 Xenon Pharmaceuticals shares in Q4 2018, an estimated $7.01M.
Opaleye Management first reported a position in Xenon Pharmaceuticals in Q3 2015 and held it in 8 quarters.
Opaleye Management's Xenon Pharmaceuticals position peaked at $7.01M in Q3 2018.
58 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2018.

Based on Opaleye Management's 13F filing for Q4 2018, filed 14 Feb 2019.